Former OtisMed CEO Sentenced To Two Years For Selling FDA-Rejected Knee Devices
This article was originally published in The Gray Sheet
Executive Summary
The sentencing, which also includes an additional one year of supervised release and a $75,000 fine, concludes a long-running investigation into the firm, which is now a subsidiary of Stryker.